Cargando…
Biodistribution and Efficacy Studies of the Proteasome Inhibitor BSc2118 in a Mouse Melanoma Model
Inhibition of the proteasome offers many therapeutic possibilities in inflammation as well as in neoplastic diseases. However, clinical use of proteasome inhibitors is limited by the development of resistance or severe side effects. In our study we characterized the anti-tumor properties of the nove...
Autores principales: | Mlynarczuk-Bialy, Izabela, Doeppner, Thorsten R., Golab, Jakub, Nowis, Dominika, Wilczynski, Grzegorz M., Parobczak, Kamil, Wigand, Moritz E., Hajdamowicz, Malgorzata, Biały, Łukasz P., Aniolek, Olga, Henklein, Petra, Bähr, Mathias, Schmidt, Boris, Kuckelkorn, Ulrike, Kloetzel, Peter-M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225687/ https://www.ncbi.nlm.nih.gov/pubmed/25389452 http://dx.doi.org/10.1016/j.tranon.2014.07.002 |
Ejemplares similares
-
LDL suppresses angiogenesis through disruption of the HIF pathway via NF-κB inhibition which is reversed by the proteasome inhibitor BSc2118
por: Yao, Gang, et al.
Publicado: (2015) -
Entosis: From Cell Biology to Clinical Cancer Pathology
por: Mlynarczuk-Bialy, Izabela, et al.
Publicado: (2020) -
Mapping of O-GlcNAc Sites of 20 S Proteasome Subunits and Hsp90 by a Novel Biotin-Cystamine Tag
por: Overath, Thorsten, et al.
Publicado: (2012) -
Fate of Entosis: From the Beginning to the End in Untreated Advanced Breast Cancer
por: Dziuba, Ireneusz, et al.
Publicado: (2023) -
Classification of Cell-in-Cell Structures: Different Phenomena with Similar Appearance
por: Borensztejn, Karol, et al.
Publicado: (2021)